Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON47340
NL-OMON47340CompletedPhase 2

A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U. - HOVON 130 NH

HOVO0 sites82 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
82
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •1. DLBCL or BCL-U, histologically confirmed according to the WHO classification 2008 with a MYC rearrangement as determined by FISH comprising:
  • •- single hit (SH MYC+ lymphoma, not fulfilling the criteria for Burkitt Lymphoma ) or
  • •- double hit lymphoma (DH) MYC+/BCL2+ or MYC+/BCL6+ or
  • •- triple hit lymphoma (TH) MYC+/BCL2+/BCL6+
  • •2. Age * 18 year
  • •3. No prior treatment except
  • •- local radiation or short course (max 7 days) steroids (max 100 mg/day)
  • •- 1 course of R-CHOP in case MYC positivity became evident during first cycle of treatment
  • •4. WHO performance status (PS) 0-3, status 4 only if disease related (see appendix C)
  • •5. Ann Arbor stage II-IV
  • •6. Measurable disease: on contract-enhanced CT scan at least 1 lesions/node with a long axis of >1.5 cm and at least one positive lesion on 18-F-FDG-PET scan.
  • •7. Negative pregnancy test at study entry
  • •8. Patient is willing and able to adhere to the requirements of the lenalidomide Pregnancy Prevention Risk Management Program
  • •9. Written informed consent

Exclusion Criteria

  • •1. All histopathological diagnoses other than DLBCL not otherwise specified or BCL-U according to the WHO classification 2008 (like Burkitt lymphoma, DLBCL associated with chronic inflammation), irrespective of the presence of MYC rearrangement
  • •2. Known history of indolent lymphoma, or presence of indolent lymphoma in the diagnostic lymph node. If during screening localization of an indolent lymphoma in the bone marrow biopsy is diagnosed, the patient is eligible.
  • •3. Absence of contrast-enhanced CT scan (neck, thorax, abdomen, pelvis) and 18F-FDG PET scan performed before first cycle of R-CHOP
  • •4. Inadequate renal function or creatinine clearance < 30 mL/min (after rehydration)
  • •5. Inadequate hepatic function: bilirubin > 3 times ULN (total) except patients with Gilbert's syndrome as defined by > 80% unconjugated bilirubin
  • •6. Inadequate hematological function: ANC < 1.0x109/L or platelets < 75x109 /L unless lymphoma related
  • •7. CNS localization of the lymphoma. Liquor analysis before start of treatment is only necessary in case of suspicion
  • •8. Female subject pregnant or breast-feeding
  • •9. History of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma
  • •10. Active symptomatic ischemic heart disease, myocardial infarction, or congestive heart failure within the past year. If echo or MUGA is obtained the LVEF should exceed 40%
  • •11. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, cancer, etc.) that would jeopardize the patient's ability to receive the regimen with reasonable safety
  • •12. HIV positivity
  • •13. Active Hepatitis B or C infection as defined by positive serology and transaminitis. Non-active Hepatitis B carriers may be included if protected with lamivudine
  • •14. Severe pulmonary dysfunction (CTCAE grade III-IV, see appendix D)
  • •15. Severe neurological or psychiatric disease
  • •16. Current participation in another clinical trial interfering with this trial
  • •17. Any psychological, familial, sociological and geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • •18. Claustrofobia to the extent that PET-CT is impossible

Investigators

Sponsor
HOVO

Similar Trials

Recruiting
Not Applicable
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U.Diffuse large B cell lymphoma, DLBCL, BCL-U, MYC
NL-OMON24704HOVO72
Active, not recruiting
Phase 1
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCLMYC positive diffuse large B cell lymphoma and Burkitt lymphomaMedDRA version: 20.0Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004943MedDRA version: 20.0Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 100000004943
EUCTR2014-002654-39-BEHOVON Foundation85
Active, not recruiting
Phase 1
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL
EUCTR2014-002654-39-NLHOVON Foundation85
Active, not recruiting
Not Applicable
XINACT: To evaluate the benefit of specific drug combinations in reducing cancer tissue in the breast in women who have large breast cancers but confined to the breast and draining lymph glands.
EUCTR2007-003221-25-GBnited Lincolnshire Hospitals NHS Trust120
Completed
Not Applicable
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancer
ISRCTN30851756VU University Medical Center (The Netherlands)200